Ninety One North America Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 477,929 shares of the company’s stock after selling 1,013 shares during the quarter. Johnson & Johnson accounts for 3.4% of Ninety One North America Inc.’s portfolio, making the stock its 9th largest position. Ninety One North America Inc.’s holdings in Johnson & Johnson were worth $74,079,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Scotia Capital Inc. lifted its position in Johnson & Johnson by 1.6% during the 4th quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock worth $195,247,000 after buying an additional 17,440 shares in the last quarter. Duality Advisers LP bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,342,000. Beacon Harbor Wealth Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $509,000. Modera Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 18.0% in the 4th quarter. Modera Wealth Management LLC now owns 44,189 shares of the company’s stock valued at $7,806,000 after purchasing an additional 6,738 shares during the period. Finally, Tiedemann Advisors LLC raised its holdings in shares of Johnson & Johnson by 20.3% in the 1st quarter. Tiedemann Advisors LLC now owns 9,017 shares of the company’s stock valued at $1,398,000 after purchasing an additional 1,519 shares during the period. 67.57% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on JNJ. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday. Citigroup began coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price on the stock. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 price target on shares of Johnson & Johnson in a research note on Friday. Finally, Atlantic Securities decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Eight equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $171.60.
Insider Activity at Johnson & Johnson
Johnson & Johnson Stock Performance
NYSE JNJ opened at $171.10 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $444.64 billion, a price-to-earnings ratio of 34.64, a P/E/G ratio of 2.88 and a beta of 0.55. The firm’s 50 day simple moving average is $160.60 and its 200 day simple moving average is $161.20. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.59 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- What Are Growth Stocks and Investing in Them
- 3 Housing Stocks to Avoid as Interest Rates Rise
- How to Invest in Electric Cars
- AMC: Is a Big Squeeze in the Coming Attractions?
- How to Invest in Blue Chip Stocks
- Rivian: A Roaring Rise Or Time To Cash Out?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
